News | January 30, 2026
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
The new functionality complements Parse’s existing Evercode immune products
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
Subscribe To Our Newsletter & Stay Updated
